Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| British Lung Foundation | OTHER |
Following on from a 10 year study conducted in Finland this study is designed to test the validity and sustainability of an enhanced asthma management model for the UK.
The British Lung Foundation (BLF) aims to work with the governments in the four UK nations to launch an asthma initiative designed to improve asthma management and outcomes. The project incorporates key learning from a 10 year programme in Finland designed to improve asthma care and cap healthcare costs for paediatric and adult populations.
The Finland programme focused on accurate diagnosis, training and education of healthcare professionals and patients and early use of anti-inflammatory therapy. The programme successfully improved medication compliance, reduced asthma hospital admissions, reduced asthma-related benefit claims and reduced the overall cost of asthma to the Finnish Government.
To test the validity and sustainability of an enhanced asthma management model for the UK, the BLF proposes to undertake a pilot initiative in England. The pilot will focus on: improving diagnostic accuracy through analysis of GP asthma registers; increasing asthma education among healthcare professionals; assessment of risk and control of patient's asthma; supportive self-management and education of people with asthma.
It is anticipated that the pilot will lead to measureable and significant improvements in asthma management, including:
The pilot will also aim to increase the proportion of patients on the asthma register with an asthma management plan and a recorded asthma control test therefore supporting higher levels of control, and will promote peer-to-peer health care professional asthma education and knowledge sharing to establish an asthma-training legacy.
The pilot model will be sustainable and reproducible across England and the devolved nations (Scotland, Wales and Northern Ireland). Whilst the core aspects of an agreed national model will be rolled out across the pilot site, it will be tailored and refined through local collaboration (primary care, secondary care and commissioners) to help attain local targets in line with regional differences, needs and priorities.
Results from the pilot will be reported 15 months after project initiation on site (July/August 2014)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with an asthma diagnosis | |||
| Patients where there is diagnostic doubt |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Exacerbations reduction | An exacerbation is defined (in line with the European Respiratory Society/American Thoracic Society guidelines) as: acute oral steroids, out of hours or Accident and Emergency (A&E) attendance for asthma, or hospitalisation for asthma. Rationale for selecting exacerbations as the primary outcome:
| 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| 1. Increased assessment of patients with equivocal diagnoses and reduction of diagnostic doubt (also detailed under process outcomes) | 1 year | |
| 2. Hospitalisations ¬- number and rate - coded for: • Asthma • Lower respiratory conditions (including asthma), i.e. "asthma-related" events |
| Measure | Description | Time Frame |
|---|---|---|
| 1. Accident and Emergency (A&E) attendance | 1 year | |
| 2. Proportion of patients on each asthma register that have a confirmed asthma diagnosis | 1 year | |
| 3. Proportion of patients with an asthma management plan |
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
The patient questionnaire will be subject to local refinement in line with local needs, targets and priorities but will assess -
The practice and patient reports will be used to characterise the patient in terms of risk and control. They will give a complete picture of the patient's asthma and will be used to identify patients for diagnostic assessment, medical management and education. Patients will then be stratified into Group 1 (patients with asthma) or Group 2 (Patients identified for further diagnostic assessment and/or with diagnostic doubt).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Price | Reasearch in Real Life Ltd | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| 3. Inhaled corticosteroids adherence | 1 year |
| 4. Referral rate of high-risk patients to local specialist | 1 year |
| 5. British Asthma Guideline adherence: appropriate step-wise management of patients | 1 year |
| 1 year |
| 4. Proportion of patients with a recorded asthma control test (ACT) and Royal College of Physician three questions (RCP3) | 1 year |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |